TCRT Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

03
Price $0.82
Market Cap (MRQ) $2M
P/E (TTM) -0.4
EPS (TTM) $-1.90
Revenue (TTM) $3.0K
ROE (TTM) -185.9%
52W Range $1–$5

TCRT Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

04
range
bars

Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.

Stock splits 2
Ex-date Split Type
July 18, 2024 1-for-10 Reverse
Feb. 1, 2024 1-for-15 Reverse

About Alaunos Therapeutics, Inc. - Common Stock Company overview from Wikipedia

05 · wikidata
sectorHealthcare industryBiotechnology employees1 countryUS

10-Year Performance Revenue, net income, margins and EPS trends

06
Revenue$5.0K
2017-12-31 → 2025-12-31
EPS$-2.20
2016-12-31 → 2025-12-31
Free Cash Flow·
2016-12-31 → 2023-12-31
Net margin-133666.7%
2021-12-31 → 2023-12-31
Valuation & Ratios 07–12

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric 5Y trend TCRT 5Y avg Peer Median Verdict
P/E (TTM) -0.45Y avg ≈-96.4 ≈-96.4 · ·
P/S (TTM) 679.55Y avg ≈43478.1 ≈43478.1 · ·
P/B (MRQ) 3.15Y avg ≈414.4 ≈414.4 · ·
Price / Tangible Book 3.55Y avg ≈249.7 ≈249.7 · ·

Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.

value · ≈ 5Y avg · industry median · verdict relative to median

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

14
Avg Surprise -0.51%
Next Report Nov 12, 2026
PeriodReportEPS ActualEPS EstSurprise
Dec. 31, 2023 $-4.90 $-4.59 -6.8%
Sept. 30, 2023 $-6.00 $-5.36 -12.0%
June 30, 2023 $-6.00 $-6.73 10.9%
March 31, 2023 $-6.00 $-6.38 5.9%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

15
Income Statement 14
Metric Trend 202520242023202220212020201920182017201620152014
Revenue $5.0K$10.0K$5.0K$3M$398.0K$0·$146.0K$16M···
R&D Expense $1M$362.0K$16M$25M$50M$53M$38M$34M$45M$158M$107M$33M
SG&A Expense $3M$4M$12M$13M$28M$28M$20M$20M$15M$14M$18M$12M
Operating Expenses $4M$5M$34M$38M$78M$80M$58M$54M$60M···
Operating Income $-4M$-5M$-34M$-35M$-78M$-80M$-58M$-54M$-53M$-165M$-120M$-43M
Interest Expense ··$2M$3M$1M·······
Other Non-op $80.0K$133.0K$1M$529.0K$-13.0K$385.0K$813.0K$631.0K$465.0K$134.0K$12.0K$-5.0K
Income Tax $0···········
Net Income $-4M$-5M$-5M$-38M$-79M$-80M$-118M$-53M$-54M$-165M$-120M$-32M
EPS (Basic) $-2.20$-2.92$-21.97$-2.61$-0.37$-0.38$-0.70$0.96$-0.53$-1.32··
EPS (Diluted) $-2.20$-2.92$-21.97$-2.61$-0.37$-0.38$-0.70$0.96$-0.53$-1.32··
Shares (Basic) 1,948,3571,601,2521,599,53214,475,354214,399,074209,636,456167,952,114143,508,674136,938,264130,391,463··
Shares (Diluted) 1,948,3571,601,2521,599,53214,475,354214,399,074209,636,456167,952,114143,710,160136,938,264130,391,463··
EBITDA ··$-34M$-35M$-78M$-80M·$-54M·$-165M$-120M$-43M
Balance Sheet 22
Metric Trend 202520242023202220212020201920182017201620152014
Cash & Equivalents $1M$1M$6M$39M$76M$115M$80M$62M$71M$81M$141M$43M
Receivables $3.0K$5.0K$1.0K$4.0K$1M$5M$3M$2M$19.0K$21.0K$446.0K$145.0K
Prepaid Expense $600.0K$2M$2M$799.0K$2M$11M$22M$21M$20M$24M$11M$1M
Current Assets $2M$3M$8M$54M$79M$131M$105M$84M$91M$105M$153M$44M
PP&E (Net) $91.0K$0$2.0K$8M$11M$10M$1M$1M$1M$843.0K$581.0K$531.0K
PP&E (Gross) $98.0K$15.0K$15.0K$18M$18M$15M$6M$5M$5M$4M$4M$3M
Accum. Depreciation $7.0K$15.0K$13.0K$10M$7M$5M$5M$4M$4M$3M$3M$3M
Other Non-current Assets ··$0$500.0K$631.0K$745.0K$110.0K$10M$13M$493.0K$494.0K$491.0K
Total Assets $3M$3M$8M$65M$95M$146M$109M$95M$106M$106M$154M$45M
Accounts Payable $613.0K$516.0K$616.0K$1M$1M$960.0K$906.0K$707.0K$4M$156.0K$2M$2M
Accrued Liabilities $200.0K$176.0K$1M$5M$6M$17M$11M$9M$10M$9M$9M$7M
Current Liabilities $813.0K$692.0K$2M$24M$16M$18M$13M$9M$21M$16M$18M$11M
Capital Leases ·····$4M······
Other Non-current Liabilities ··$0$28.0K$0·······
Total Liabilities $813.0K$692.0K$2M$26M$37M$22M$14M$9M$58M$58M$66M$11M
Long-term Debt ··$0$17M$24M$0······
Total Debt ··$0$17M$24M·······
Common Stock $2.0K$2.0K$2.0K$16.0K$216.0K$215.0K$182.0K$161.0K$143.0K$132.0K$132.0K$104.0K
Retained Earnings $-925M$-920M$-916M$-881M$-843M$-764M$-684M$-566M$-712M$-658M$-493M$-373M
Stockholders' Equity $2M$2M$6M$39M$58M$124M$95M$86M$-97M$-77M$87M$34M
Liabilities + Equity $3M$3M$8M$65M$95M$146M$109M$95M$106M$106M$154M$45M
Shares Outstanding 2,349,4801,601,2521,601,25216,027,384216,127,443214,591,906181,803,320161,066,136142,658,037132,376,670131,718,579104,452,105
Cash Flow 15
Metric Trend 202520242023202220212020201920182017201620152014
D&A ·········$290.0K$357.0K$462.0K
Stock-based Comp $796.0K$435.0K$3M$4M$11M$7M$6M$8M$8M$8M$8M$5M
Restructuring ·$0$1M$0········
Operating Cash Flow $-3M$-5M$-30M$-29M$-61M$-57M$-41M$-49M$-55M$-58M$-10.0K$-37M
CapEx $98.0K$0$197.0K$216.0K$3M$10M$284.0K$459.0K$737.0K$551.0K$412.0K$193.0K
Investing Cash Flow $-98.0K$0$1M$-193.0K$-3M$-10M$-284.0K$-459.0K$-737.0K$-551.0K··
Debt Issued ···$0$25M$0······
Net Debt Issued ··$-18M$-8M$25M·······
Stock Issued ·$0$92.0K$15M$0···$47M·$94M·
Stock Repurchased ··$0$45.0K$0·$653.0K$2M$0$2.0K$34.0K$544.0K
Net Stock Activity ··$92.0K$15M···$-2M·$-2.0K$94M$-544.0K
Financing Cash Flow $3M$0$-18M$6M$26M$102M$59M$40M$45M$-788.0K··
Net Change in Cash $294.0K$-5M$-47M$-23M$-39M$35M$18M$-10M$-10M$-60M$98M$-25M
Taxes Paid ·······$0$0$0··
Free Cash Flow ··$-30M$-29M$-65M$-67M·$-50M·$-59M$-422.0K$-37M
Profitability 5
Metric Trend 202520242023202220212020201920182017201620152014
Operating Margin ··-685340.0%-1201.4%-19484.7%·······
Net Margin ··-702800.0%-1291.2%-19786.7%·······
EBITDA Margin ··-685340.0%-1201.4%-19484.7%·······
ROA ··-96.0%-47.2%-65.3%-62.6%·-52.9%·-127.1%-120.7%-54.3%
ROE ··-347.8%-106.8%-124.2%-59.5%·149.9%·-3282.0%-198.2%-76.4%
Liquidity & Solvency 5
Metric Trend 202520242023202220212020201920182017201620152014
Current Ratio ··4.22.24.97.1·8.9·6.68.44.1
Quick Ratio ··3.11.64.86.5·6.7·5.17.84.0
Debt / Equity ··0.00.40.4·······
LT Debt / Equity ··0.00.00.3·······
Interest Coverage ··-17.8-11.1········
Efficiency 2
Metric Trend 202520242023202220212020201920182017201620152014
Asset Turnover ··0.00.00.0·······
Receivables Turnover ··2.05.20.1·······
Per Share 5
Metric Trend 202520242023202220212020201920182017201620152014
Book Value / Share ··$0.39$0.16$0.27$0.58·$0.53·$-0.58$0.66$0.32
Revenue / Share ··$0.00$0.01········
Cash Flow / Share ··$-1.88$-0.13·$-0.27·$-0.34····
Cash / Share ··$0.38$0.16$0.35$0.54·$0.38·$0.61$1.07$0.41
EPS (TTM) $-2.20$-2.92$-21.97$-2.61$-0.37$-0.38$-0.70$0.96$-0.53$-1.32··
Growth Rates 2
Metric Trend 202520242023202220212020201920182017201620152014
Revenue YoY -50.0%100.0%-99.8%634.2%········
Revenue CAGR 3Y -88.0%-70.7%··········
Valuation (TTM) 14
Metric Trend 202520242023202220212020201920182017201620152014
Revenue TTM $5.0K$10.0K$5.0K$3M$398.0K$0·$146.0K$16M$800.0K$800.0K$800.0K
Net Income TTM $-4M$-5M$-5M$-38M$-79M$-80M$-118M$-53M$-54M$-165M$-120M$-32M
Market Cap ··$168M$23.44B$35.34B$81.12B·$45.18B·$106.23B$164.19B$79.44B
Enterprise Value ··$162M$23.42B$35.28B·······
P/E -1.5-0.7-0.5-37.4-441.9-994.7-1011.4292.2-1171.7-608.0··
P/S ··33626.38021.988786.0··309445.6·132790.3205234.099294.8
P/B ··26.7608.0608.7654.3·528.0·-1374.31879.22347.3
P / Tangible Book 3.51.526.7608.0608.7654.3······
P / Cash Flow ··-5.6-801.9-574.9-1422.8·-913.5·-1821.4-16418720.9-2167.4
P / FCF ··-5.5-796.0-545.4-1214.5·-905.1·-1804.3-389069.2-2156.1
EV / EBITDA ··-4.7-667.1-455.0·······
EV / FCF ··-5.3-795.2-544.6·······
EV / Revenue ··32413.98014.388655.5·······
Earnings Yield -68.1%-152.9%-209.2%-2.7%-0.23%-0.10%-0.10%0.34%-0.09%-0.16%··

Most recent period on the left · null values shown as ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

16
Metric 2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue $5.0K $10.0K $5.0K $3M $398.0K
Operating Margin % · · -685340.0% -1201.4% -19484.7%
Net Income $-4M $-5M $-5M $-38M $-79M
Diluted EPS $-2.20 $-2.92 $-21.97 $-2.61 $-0.37

Institutional owners (13F) 33 filers · $302K total · As of June 30, 2026

17

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Holders 33
Value held $302K
New positions 6
Exited positions 4
Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
6 (0 vs prior Q) 4 (+2 vs prior Q) 6 (0 vs prior Q) 3 (-1 vs prior Q) -36K

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
VANGUARD GROUP INC $97,096 30,061 32.12% Shares
BlackRock, Inc. $48,258 21,353 15.96% Shares
GEODE CAPITAL MANAGEMENT, LLC $43,753 19,356 14.47% Shares
VANGUARD FIDUCIARY TRUST CO $35,023 15,497 11.59% Shares
VANGUARD CAPITAL MANAGEMENT LLC $31,782 14,063 10.51% Shares
CITADEL ADVISORS LLC $26,826 11,870 8.87% Shares
OSAIC HOLDINGS, INC. $3,907 1,731 1.29% Shares
Tower Research Capital LLC (TRC) $3,663 1,621 1.21% Shares
Arax Advisory Partners $2,749 1,216 0.91% Shares
UBS Group AG $2,242 992 0.74% Shares
MORGAN STANLEY $1,889 836 0.62% Shares
Vanguard Global Advisers, LLC $1,132 501 0.37% Shares
ROYAL BANK OF CANADA $1,000 375 0.33% Shares
WELLS FARGO & COMPANY/MN $877 388 0.29% Shares
CIBC Private Wealth Group LLC $723 300 0.24% Shares
Blue Trust, Inc. $305 135 0.10% Shares
Steward Partners Investment Advisory, LLC $253 112 0.08% Shares
Federation des caisses Desjardins du Quebec $158 70 0.05% Shares
BOKF, NA $149 66 0.05% Shares
Axiom Investment Management LLC $104 46 0.03% Shares
Key Financial Inc $54 24 0.02% Shares
SIGNATUREFD, LLC $52 23 0.02% Shares
NFSG Corp $47 21 0.02% Shares
LANARK FINANCIAL, INC. $45 20 0.01% Shares
AdvisorNet Financial, Inc $43 19 0.01% Shares
BARCLAYS PLC $34 15 0.01% Shares
Sunbelt Securities, Inc. $29 10 0.01% Shares
Inspire Investing, LLC $25 9 0.01% Shares
WEST PACES ADVISORS INC. $23 10 0.01% Shares
CWM, LLC $23 8 0.01% Shares
IFG Advisory, LLC $14 6 0.00% Shares
BNP PARIBAS FINANCIAL MARKETS $14 6 0.00% Shares
Tidemark, LLC $5 2 0.00% Shares

Activists & 5%+ owners 11 positions

18

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
Price Adrian, Chris Butterworth, Richard Jones, Edward Jones, Gareth Downing, Richard Kotey, Chris Cole, Arif Chaudrey, Emma Babb, Colin Craig, John Nicholls, Carl Ware, Andrew Turner, Matthew Robbins, Phillip James Stead, Stephen Hennessy, Greg Arnold, Michelle Douglas, HexagonONE Ltd, Alimenta Holding Limited, Krakatau Holding Limited ×3 filings March 5, 2026 8.60% Amendment Board campaign SEC
Chris Butterworth, Richard Jones, Edward Jones, Gareth Downing, Richard Kotey, Chris Cole, Arif Chaudrey, Emma Babb, Colin Craig, John Nicholls, Carl Ware, Andrew Turner, Matthew Robbins, Phillip James Stead, Stephen Hennessy, Greg Arnold, Michelle Douglas, Price Adrian ×2 filings Oct. 31, 2025 8.60% Amendment · SEC
PMGC CAPITAL LLC, PMGC Holdings Inc. ×2 filings Sept. 5, 2025 0.00% Amendment · SEC
WaterMill Asset Management Corp., Postma Robert W July 1, 2025 9.00% Initial filing · SEC
RANDAL J. KIRK ×8 filings Dec. 12, 2018 · Initial filing · SEC
Oct. 15, 2018 · Initial filing · SEC
July 6, 2016 · Initial filing · SEC
RANDAL KIRK June 9, 2015 · Initial filing · SEC
Millennium Partners, L.P., Millenco LLC, Millennium Management LLC, Israel A. Englander ×3 filings June 18, 2009 · Initial filing · SEC
Undisclosed reporting person, Undisclosed reporting person Sept. 27, 2005 · Initial filing · SEC
Lindsay A. Rosenwald, M.D. Sept. 23, 2005 · Initial filing · SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Company insiders 46 insiders · 22 officers · 26 directors

19
Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Dale Curtis Hogue Jr. Chief Executive Officer, Interim March 29, 2025 A · 0 0 $0
Kevin S. Boyle Sr. Chief Executive Officer Sept. 1, 2023 S 798,236 0 0 $0
Laurence James Neil Cooper President and CEO Jan. 4, 2021 S 1,799,280 0 0 $0
Jonathan Lewis CEO Dec. 31, 2014 A 744,145 0 0 $0
Sath Shukla EVP, Chief Financial Officer Jan. 29, 2020 A 80,500 0 0 $0
Jason Amello Executive Vice President & CFO May 8, 2013 F 22,377 0 0 $0
David M Mauney MD President Jan. 29, 2020 A 275,778 0 0 $0
Hagop Youssoufian President of R&D and CMO Dec. 31, 2012 A 92,721 0 0 $0
Richard E Bagley President, COO & Treasurer Dec. 31, 2011 F 211,239 0 0 $0
Caesar J Belbel COO, CLO, and Secretary Dec. 31, 2017 F 207,434 0 0 $0
Ferdinand Groenewald Vice President of Finance Aug. 18, 2025 A 10,775 0 0 $0
Melinda Lackey Legal & Administration March 29, 2025 A · 0 0 $0
Abhishek K Srivastava Vice President, Technical Operations March 15, 2023 A · 0 0 $0
Drew Deniger Vice President, Research and Development March 15, 2023 A · 0 0 $0
Michael Wong Vice President, Finance March 15, 2023 A · 0 0 $0
Eleanor De Groot EVP, Operations March 30, 2022 A 237,106 0 0 $0
Raffaele Baffa Chief Medical Officer May 17, 2021 A 280,645 0 0 $0
Jill Buck EVP, GM Gene Therapy March 4, 2021 A 231,016 0 0 $0
Robert Hadfield Chief Legal Officer and Sec. March 4, 2021 A 176,819 0 0 $0
Kevin G Lafond SVP, Treasurer & CAO Jan. 8, 2021 S 63,965 0 0 $0
Francois Lebel Executive Vice President R&D Dec. 31, 2017 F 200,566 0 0 $0
Robert Peter Gale Senior V.P. of Research April 26, 2006 A · 0 0 $0
Michael Allen Jerman Director July 23, 2026 A 23,759 0 0 $0
Jaime Vieser Director July 23, 2026 A 47,642 0 0 $0
Postma Robert W Director July 23, 2026 A 58,609 0 0 $0
Robert Hofmeister Director June 6, 2024 A · 0 0 $0
James Huang Director June 6, 2023 A 188,333 0 0 $0
Mary Thistle Director June 6, 2023 A 45,000 0 0 $0
Christopher Bowden Director June 22, 2022 A 44,167 0 0 $0
Heidi Hagen Director Sept. 2, 2021 P 145,889 0 0 $0
Kevin J Buchi Director March 4, 2021 A 4,167 0 0 $0
Scott Braunstein Director Dec. 31, 2019 A 31,780 0 0 $0
Douglas W. Pagan Director Dec. 31, 2019 A 35,943 0 0 $0
Elan Ezickson Director Dec. 31, 2019 F 71,887 0 0 $0
Scott Tarriff Director Dec. 31, 2019 A 4,186 0 0 $0
James Anthony Cannon Director May 7, 2019 M 398,050 0 0 $0
Murray Brennan Director Dec. 30, 2017 F 72,620 0 0 $0
Wyche Fowler Director Dec. 30, 2017 F 156,446 0 0 $0
Michael Weiser Director Dec. 30, 2017 F 224,282 0 0 $0
RANDAL J. KIRK Director Aug. 31, 2016 J 122,309 0 0 $0
Timothy Mcinerney Director Dec. 31, 2014 F 372,120 0 0 $0
George B Abercrombie Director April 5, 2010 A 25,000 0 0 $0
Gary S Fragin Director March 31, 2010 A 67,500 0 0 $0
ESSEX WOODLANDS HEALTH VENTURES FUND VI L P 10% owner Dec. 8, 2009 P 2,371,642 0 0 $0
Lindsay A. Rosenwald, M.D. 10% owner May 3, 2006 J · 0 0 $0
Holger Weis · Aug. 6, 2026 A 25,483 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

ETF ownership Held by 1 ETF

20

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund Weight Units As of Source
VXF · VANGUARD INDEX FUNDS 0.00% 14,063 SH Aug. 19, 2026 Daily

TCRT Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

21
rating · 6 analysts SELL
0 0.0% Strong Buy
0 0.0% Buy
3 50.0% Hold
1 16.7% Sell
2 33.3% Strong Sell

Peer comparison (GICS sub-industry) Key metrics vs sector peers

22

FY basis, prices as of each company's last fiscal year-end close.

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
TCRT · -1.5 -50.0% · · ·
SILO $5M -0.7 0.00% -5863.5% -75.3% 38.6%
LABT · · · · · ·

My Metrics Your personal watchlist — selected rows from Full Fundamentals

26

Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Source: SEC 10-Q filed Aug 14, 2026